Skip to main content
OpenTrials
Completed

NCT Number: NCT01810627

Application of Megavoltage Imaging to Reduce Artifact After Seed Implants

This is a non-randomized study to evaluate the utility of MVCT as a quality assurance measure in patients treated with interstitial permanent seed implants for low and intermediate risk prostate cancer. All patients will received the same standard of care treatment but will receive an additinoal CT image of the prostate.

Completed

Looking for future studies?

Notify Me

Key information

Age range

50 year–80 year

Sex eligibility

Male

Study type

Observational

Primary location

Markey Cancer Center

Lexington, Kentucky, 40536, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Male 50-80 years of age Eligible for interstitial brachytherapy implants

Exclusion criteria

-

Treatment and study plan

MVCT

Radiation

Patients will receive an additional MVCT scan at their one month follow up visit.

Primary outcomes

  1. Change in prostate volume measured in cm^3

    Time frame: One month post implant

    Change in prostate volume measured with trans-rectal ultrasound at baseline versus prostate volume measured with KVCT and MVCT.

Sponsors and collaborators

Lead sponsor

William St Clair

Other

Registry information

Official study title

Application of Megavoltage Imaging to Reduce Artifact Following Interstitial Seed Implants for Prostate Adenocarcinoma

Important dates

Study start
2013
Primary completion
2016
Study completion
2016
First posted
Mar 13, 2013
Registry last updated
Sep 26, 2017

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.